First In Human By Vial Vial

Explore the untapped potential of RNA amplifying therapeutics with the  CEO of CAMP4 Therapeutics, Josh Mandel-Brehm. We uncover the power of antisense oligonucleotides in rewriting the narrative for genetic diseases characterized by protein deficiency. Josh takes us behind the scenes of their innovative RNA Actuating Platform (RAP), a map charting the course of gene expression and a guide to the regulatory RNAs that can turn up the volume on genes gone silent due to disease. It's a pioneering journey through the promising avenues of metabolic disease treatment, with a special spotlight on their developmental star, CMP-CPS-001.

First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. 

Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.

🎧 Stay in the Loop!

For the latest news and updates, visit our website: https://vial.com

Follow us on social media for real-time insights:

Twitter: https://twitter.com/VialTrials

LinkedIn: https://www.linkedin.com/company/vialtrials

Embark on a journey through the neurons and synapses of brain science with William Korinek, the CEO of Astrocyte Pharmaceuticals. In a conversation that fuses the molecular intricacies of neuroprotection with the humanistic pursuit of medical advancement, Bill reveals his unique path from molecular biologist to biotech innovator. Together, we unravel the complexities of securing funding, the importance of strategic networking, and the scarcity of research dollars for conditions impacting millions globally. His insights into the world of neuroprotection therapies, especially the uncharted potential of astrocytes, promise to leave you enlightened and curious about the future of neurological care.

First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. 

Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.

🎧 Stay in the Loop!

For the latest news and updates, visit our website: https://vial.com

Follow us on social media for real-time insights:

Twitter: https://twitter.com/VialTrials

LinkedIn: https://www.linkedin.com/company/vialtrials

In this episode, Rachel Haines from Rinri Therapeutics joins us to discuss the possibilities of cell therapy for hearing loss. Our conversation with Rachel goes beyond just scientific innovation; we also explore the potential impact of Rinri's upcoming human trials, which are based on Professor Marcelo Rivolta's groundbreaking work. By delving into the challenges and excitement of pioneering clinical trials in uncharted territory, we envision a future where natural hearing restoration could become a reality.

First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.

Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.

🎧 Stay in the Loop!

For the latest news and updates, visit our website: https://vial.com

Follow us on social media for real-time insights:

Twitter: https://twitter.com/VialTrials

LinkedIn: https://www.linkedin.com/company/vialtrials

Join as we dive deep into the world of oncology drug development with Bas van der Baan of Lixte. Discover the inspiration behind Lixte's focus on PP2A inhibitors and how this innovative approach is poised to revolutionize cancer treatment by enhancing chemotherapy and immunotherapy responses. Bas shares insights into ongoing clinical trials, regulatory considerations, and Lixte's ambitious long-term goals in expanding their impact on cancer care. Tune in to explore the cutting-edge science and vision driving Lixte's journey in the fight against cancer.

First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.

Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.

🎧 Stay in the Loop!

For the latest news and updates, visit our website: https://vial.com

Follow us on social media for real-time insights:

Twitter: https://twitter.com/VialTrials

LinkedIn: https://www.linkedin.com/company/vialtrials

Dr. Samar Mohanty, president and CSO of Nanoscope Therapeutics joins us to shed light on the revolutionary gene therapy that's giving hope to individuals with retinal degenerative diseases by pioneering a treatment that can re-sensitize the retina to detect low light levels. We open the curtains on their groundbreaking multi-characteristic opsins (MCOs), which have the potential to address all forms of retinal degeneration and restore vision in millions of visually impaired individuals.

First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.

🎧 Stay in the Loop!

For the latest news and updates, visit our website: https://vial.com

Follow us on social media for real-time insights:

Twitter: https://twitter.com/VialTrials

LinkedIn: https://www.linkedin.com/company/vialtrials

Imagine unlocking the secrets to revitalizing the brain's energy centers and turning the tide on neurodegenerative diseases. In this episode, Rob introduces us to CNM-Au8, an oral nanotherapeutic with the potential to recharge failing mitochondria. Our discussion traverses the innovative path Clene has charted, from the drug's conception to the exciting clinical trial results that highlight its capacity to enhance neurological functions and offer new hope to individuals grappling with ALS and multiple sclerosis.

First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.

🎧 Stay in the Loop!

For the latest news and updates, visit our website: https://vial.com

Follow us on social media for real-time insights:

Twitter: https://twitter.com/VialTrials

LinkedIn: https://www.linkedin.com/company/vialtrials